All In Biotech

NDA 021658 · Azurity

Alvesco

Ciclesonide · Inhalation

Last checked: Nov 20, 2026Latest source record: Feb 16, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Jan 10, 2008

Approved uses

2

Original approval plus efficacy supplements

Registered trials

81

55 Phase 3, 1 recruiting

FAERS reports

11,143

10,133 serious, 567 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 28, 2025.

ALVESCO is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 12 years of age and older. Limitations of Use : ALVESCO is not indicated for the relief of acute bronchospasm. ALVESCO is not indicated for children under 12 years of age. ALVESCO is an inhaled corticosteroid indicated for maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 12 years of age and older. ( 1 ) Limitations of Use : ALVESCO is not indicated for the relief of acute bronchospasm or in pediatric patients less than 12 years of age. ( 1 )

Mechanism: Ciclesonide is a prodrug that is enzymatically hydrolyzed to a pharmacologically active metabolite, C21-desisobutyryl-ciclesonide (des-ciclesonide or RM1) following oral inhalation. Des-ciclesonide has anti-inflammatory activity with affinity for glucocorticoid receptors that is 120 times greater than the parent compound and 12 times greater than dexamethasone. The clinical significance of these findings is unknown. The precise mechanisms of corticosteroid action in asthma are unknown. Inflammation is recognized as an important component in the pathogenesis of asthma. Corticosteroids have...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ALVESCO · CICLESONIDE 0.16MG/INH · AEROSOL, METERED, INHALATION · Prescription
  • ALVESCO · CICLESONIDE 0.08MG/INH · AEROSOL, METERED, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ciclesonide" as an intervention, any sponsor and status, largest first.

All 81 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • asthma5,034
  • dyspnoea3,973
  • wheezing3,021
  • cough2,157
  • therapeutic product effect incomplete2,118
  • loss of personal independence in daily activities1,647
  • obstructive airways disorder1,440
  • pneumonia1,420
  • sleep disorder due to a general medical condition1,275
  • productive cough1,195
  • drug ineffective1,136
  • fatigue1,063

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20065
20078
200836
200971
2010114
2011179
2012201
2013208
2014225
2015293
2016443
2017413
2018600
2019951
20201,306
20211,966
2022893
20231,048
2024884
2025775
2026524

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Alvesco (Ciclesonide)

2024 spending

$34.9M

Beneficiaries

88,402

217,395 claims

Per beneficiary

$395

$12.84 per unit

View as table
YearSpending
2020$30,903,953
2021$31,974,256
2022$33,342,211
2023$35,011,917
2024$34,900,989

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 139 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.